Endpoints News reports that as a number of drug candidates make their way through clinical trials, many analysts believe 2023 will be an “important” year for the ongoing development of both allogeneic and autologous cell-based therapies for the treatment of multiple myeloma and non-Hodgkin's lymphoma.